Allergan (NYSE:AGN) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Friday.

Several other research firms also recently weighed in on AGN. TheStreet raised Allergan from a “d+” rating to a “c” rating in a report on Monday, August 20th. Cantor Fitzgerald reissued a “hold” rating and issued a $180.00 target price on shares of Allergan in a report on Friday, September 14th. Wells Fargo & Co set a $232.00 target price on Allergan and gave the company a “buy” rating in a report on Wednesday, August 22nd. Deutsche Bank set a $210.00 target price on Allergan and gave the company a “buy” rating in a report on Wednesday, September 12th. Finally, Morgan Stanley set a $202.00 target price on Allergan and gave the company an “overweight” rating in a report on Thursday, August 23rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $211.91.

Shares of NYSE AGN opened at $192.51 on Friday. The stock has a market cap of $63.16 billion, a price-to-earnings ratio of 11.77, a price-to-earnings-growth ratio of 1.43 and a beta of 1.21. The company has a quick ratio of 0.85, a current ratio of 1.00 and a debt-to-equity ratio of 0.34. Allergan has a 1 year low of $142.81 and a 1 year high of $217.00.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Thursday, July 26th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.13 by $0.29. The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $3.92 billion. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. Allergan’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $4.02 EPS. equities research analysts expect that Allergan will post 16.29 EPS for the current fiscal year.

In related news, Director Joseph H. Boccuzi purchased 900 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The shares were purchased at an average price of $190.59 per share, for a total transaction of $171,531.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Christopher J. Coughlin purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The stock was bought at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. Insiders own 0.36% of the company’s stock.

A number of hedge funds have recently modified their holdings of AGN. Parkside Investments LLC increased its position in Allergan by 1.8% during the 2nd quarter. Parkside Investments LLC now owns 15,845 shares of the company’s stock worth $2,830,000 after purchasing an additional 275 shares during the period. Avestar Capital LLC increased its position in Allergan by 25.1% during the 2nd quarter. Avestar Capital LLC now owns 1,483 shares of the company’s stock worth $230,000 after purchasing an additional 298 shares during the period. New Jersey Better Educational Savings Trust increased its position in Allergan by 9.4% during the 2nd quarter. New Jersey Better Educational Savings Trust now owns 3,500 shares of the company’s stock worth $584,000 after purchasing an additional 300 shares during the period. Parallel Advisors LLC increased its position in Allergan by 34.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,233 shares of the company’s stock worth $205,000 after purchasing an additional 319 shares during the period. Finally, Arvest Bank Trust Division increased its position in Allergan by 0.6% during the 1st quarter. Arvest Bank Trust Division now owns 56,243 shares of the company’s stock worth $9,465,000 after purchasing an additional 333 shares during the period. Hedge funds and other institutional investors own 77.34% of the company’s stock.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Read More: What are the most popular ETFs

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.